Abstract 1059P
Background
The impact of the duration of tumor persistence within the host – tumor longevity (TL) – on patient (pt) outcomes under immune checkpoint inhibitors (ICIs) is unexplored. We hypothesized that this time parameter may influence ICIs efficacy. We investigated this association in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and renal/urothelial cancer (R/UC) pts.
Methods
Retrospective, observational study including adult pts with primary/recurrent HNSCC, NSCLC, R/UC receiving ICIs (≥first line) in 2 Italian centers. Endpoints were the association between TL and: 1) progressive disease (PD) vs. complete response (CR)/ partial response (PR)/ stable disease (SD); 2) Common Terminology Criteria for Adverse Events (CTCAE) G≥3 toxicity; 3) overall survival (OS). Univariable/multivariable logistic regression model (for PD, toxicity) and Cox proportional hazards model (for OS) were used. TL, defined as time from cancer histological diagnosis to ICIs start, was included as continuous variable using 3 knots restricted cubic spline, comparing third (Q3) vs. first (Q1) quartiles.
Results
304 pts, diagnosed in 2002-2022, started ICIs in 2014-2022. TL had a right-skewed distribution [median: 15.3 (Q1-Q3, 5.5; 33.1) months]. CR, PR, SD, PD occurred in 16 (5.3%), 90 (29.6%), 65 (21.4%), 133 (43.7%) pts, respectively; G≥3 toxicity was reported in 16 (5.3%) pts and 231 (76.0%) pts died. Multivariable models adjusted for relevant variables (Table) suggested that longer TL was associated with lower PD odds (Odds Ratio [OR] Q3 vs. Q1 = 0.31; 95% CI 0.12; 0.81, p = 0.004), higher G≥3 toxicity odds (OR = 1.27; 95% CI 0.39; 4.12), lower death risk (Hazard Ratio = 0.79; 95% CI 0.49; 1.28). Table: 1059P
| Descriptive statistics (N=304) | ||
| Sex | Male | 243 (79.9%) |
| Age at diagnosis (years) | Mean (SD) | 64.7 (10.4) |
| Smoking history | Yes | 226 (74.3%) |
| No | 57 (18.8%) | |
| Unknown | 21 (6.9%) | |
| Primary site | NSCLC | 138 (45.4%) |
| HNSCC | 112 (36.5%) | |
| R/UC | 54 (17.8%) | |
| Stage at diagnosis | IV | 199 (65.5%) |
ConclusionsOur real-world, hypothesis-raising results indicate that longer TL may lead to improved response to ICIs, higher risk of G≥3 toxicity and longer OS. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingAuthors at Niguarda Cancer Center are supported by Fondazione Oncologia Niguarda ETS. DisclosureA. Sartore Bianchi: Financial Interests, Personal, Advisory Board: Amgen, Servier, Novartis; Financial Interests, Personal, Invited Speaker: Bayer, Guardant Health, Pierre Fabre. S. Siena: Financial Interests, Advisory Board: Agenus, Amgen, AstraZeneca, Bayer, BMS, CheckmAb, Clovis, Daiichi Sankyo, Merck, Novartis, Roche-Genentech, Seattle Genetics. L.F.L. Licitra: Financial Interests, Personal, Advisory Board, for expert opinion in advisory boards: AstraZeneca, Bayer, BMS, Eisai, MSD, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy srl, Doxa Pharma srl, Amgen, Nanobiotics, GSK; Financial Interests, Institutional, Research Grant, Funds received by my institution for clinical studies and research activities in which I am involved: AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, F. Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck-Serono, Merck Healthcare KGaA, MSD, Novartis, Pfizer, Roche, Adlai Nortye. All other authors have declared no conflicts of interest. Resources from the same session1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancersPresenter: Annarita Avanzo Session: Poster session 03 1056P - Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital recordsPresenter: Annelies Verbiest Session: Poster session 03 1057P - Blinded independent central review versus local investigator assessment of progression-free survival in randomized controlled trials of immunotherapy in advanced cancers: A systematic review and meta-analysisPresenter: Simeone D'Ambrosio Session: Poster session 03 1058P - Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequencesPresenter: Damien Bruyat Session: Poster session 03 1060P - Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A metrology informatics analysis based on machine learningPresenter: Song-Bin Guo Session: Poster session 03 1061P - Assessing differential informative censoring in control and experimental arm in trials testing immunotherapy in metastatic cancers: A systematic reviewPresenter: Filippo Vitale Session: Poster session 03 1062P - Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapyPresenter: Èlia Sais Session: Poster session 03 1063P - Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohortPresenter: Víctor Albarrán Fernández Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|